RT Journal Article
T1 A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus.
A1 Farmakis, Dimitrios
A1 Agostoni, Piergiuseppe
A1 Baholli, Loant
A1 Bautin, Andrei
A1 Comin-Colet, Josep
A1 Crespo-Leiro, Maria G
A1 Fedele, Francesco
A1 García-Pinilla, Jose Manuel
A1 Giannakoulas, George
A1 Grigioni, Francesco
A1 Gruchała, Marcin
A1 Gustafsson, Finn
A1 Harjola, Veli-Pekka
A1 Hasin, Tal
A1 Herpain, Antoine
A1 Iliodromitis, Efstathios K
A1 Karason, Kristjan
A1 Kivikko, Matti
A1 Liaudet, Lucas
A1 Ljubas-Maček, Jana
A1 Marini, Marco
A1 Masip, Josep
A1 Mebazaa, Alexandre
A1 Nikolaou, Maria
A1 Ostadal, Petr
A1 Põder, Pentti
A1 Pollesello, Piero
A1 Polyzogopoulou, Eftihia
A1 Pölzl, Gerhard
A1 Tschope, Carsten
A1 Varpula, Marjut
A1 von Lewinski, Dirk
A1 Vrtovec, Bojan
A1 Yilmaz, Mehmet Birhan
A1 Zima, Endre
A1 Parissis, John
K1 Acute heart failure
K1 Advanced heart failure
K1 Dobutamine
K1 Inodilators
K1 Inotropes
K1 Levosimendan
K1 Milrinone
K1 Norepinephrine
AB Inotropes aim at increasing cardiac output by enhancing cardiac contractility. They constitute the third pharmacological pillar in the treatment of patients with decompensated heart failure, the other two being diuretics and vasodilators. Three classes of parenterally administered inotropes are currently indicated for decompensated heart failure, (i) the beta adrenergic agonists, including dopamine and dobutamine and also the catecholamines epinephrine and norepinephrine, (ii) the phosphodiesterase III inhibitor milrinone and (iii) the calcium sensitizer levosimendan. These three families of drugs share some pharmacologic traits, but differ profoundly in many of their pleiotropic effects. Identifying the patients in need of inotropic support and selecting the proper inotrope in each case remain challenging. The present consensus, derived by a panel meeting of experts from 21 countries, aims at addressing this very issue in the setting of both acute and advanced heart failure.
YR 2019
FD 2019-09-06
LK http://hdl.handle.net/10668/14822
UL http://hdl.handle.net/10668/14822
LA en
DS RISalud
RD Apr 10, 2025